Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 8, 2010, Pages 497-503

  Park, C G ^a   Lee, H ^b   Choi, J W ^c   Lee, S J ^d   Kim, S H ^a   Lim, H E ^a  

^a Korea University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AmorePacific Corporation   (South Korea)

^d Central Research Institute   (South Korea)

Author keywords

Amlodipine; Cytochrome P 450; Drug interaction; Non concurrent dosing; Simvastatin

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; SIMVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE;

EID: 77955703973     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48497     Document Type: Article

References (25)

1. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000; 68: 122-129. (Pubitemid 30659167)
2. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002; 72: 685-691.
3. Barr WH, Aceto T, Jr, Chung M, Shukur M. Dose-dependent drug metabolism during the absorptive phase. Rev Can Biol. 1973; 32 (Suppl): 42.
4. Carvalho M, Oliveira CH, Mendes GD, Sucupira M, Moraes ME, De Nucci G. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos. 2001; 22: 383-390.
5. Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Rep. 2000; 2: 14-19.
6. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004; 34: 961-971.
7. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994; 47: 1643-1653.
8. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999; 84: 811-815.
9. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991; 34: 1838-1844.
10. Herman RJ. Drug interactions and the statins. CMAJ. 1999; 161: 1281-1286.
11. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther. 1999; 290: 1116-1125.
12. Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S. The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin. Br J Clin Pharmacol. 2000; 49: 98-103.
13. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998; 64: 177-182.
14. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000; 55: 843-852.
15. Lehto P, Kivisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1994; 38: 248-251.
16. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000; 67: 267-274.
17. Najib NM, Idkaidek N, Adel A, Admour I, Astigarraga RE, Nucci GD, Alam SM, Dham R, Qumaruzaman. Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos. 2003; 24: 183-189.
18. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008; 47: 463-474.
19. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006; 80: 565-581.
20. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res. 2005; 28: 223-227.
21. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003; 56: 120-124.
22. Sawada T, Sako K, Yoshihara K, Nakamura K, Yokohama S, Hayashi M. Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. J Pharm Sci. 2003; 92: 790-797.
23. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP-1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004; 311: 228-236.
24. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos. 1990; 18: 138-145.
25. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1988; 28: 990-994.